Sepsis-3 Study in Northeast Thailand

Sepsis Clinical Trial

— SEPSISIII  

Official title:

Utility of Sepsis-3 Definition, Causes and Factors Associated With Outcomes in Community-acquired Sepsis in Ubon Ratchathani, Northeast Thailand

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03379402
• Other study ID #: HCR17001
• Status: Recruiting
• Start date: February 1, 2018
• Est. completion date: December 31, 2024

Study information

• Verified date: July 2022
• Source: University of Oxford
• Contact: Assoc Prof. Direk Limmathurotsakul, MD
• Phone: +66-2-203-6304
• Email: direk[@]tropmedres.ac
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational study to evaluate the utility of the latest recommendation to define severity of infection for sepsis patients (sepsis-3), and to identify the aetiology and factors associated with outcome of community-acquired sepsis in Northeast Thailand. Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2700
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females 18 years old.

2. Thai nationality.

3. Required hospitalization as decided by the attending physician

4. Documented by attending physician that an infection is the primary cause of illness leading to the hospitalization. These can be infections due to any pathogens (bacteria, viruses, fungi and parasites).

5. qSOFA (quick Sepsis-related Organ Failure Assessment) score = 2 defined as 2 or more

of the following:

• Respiratory rate =22 /min or required ventilator
• Alteration of mental status (GCS<15 or 10T with endotracheal tube)
• Systolic blood pressure =100 mm Hg

Exclusion Criteria:

1. Infection is not suspected to be a primary cause of the current illness episode leading to the hospitalization. For example, community-acquired sepsis is considered to be due to stroke, cardiovascular diseases, acute myocardial infarction, cancer, burn, injury, and trauma.

2. Hospitalized at the study site for this current episode for more than 24 hours before enrollment.

3. Hospitalized for this current episode for more than 72 hours at another primary/referring hospital

4. Prior to this current episode, the patient was admitted to any hospital within the last 30 days.

5. Prior to enrolment, it is documented by the attending physician that hospital acquired infection is associated with the cause of sepsis. Please note that the following conditions are not exclusion criteria, and patients with the following conditions can be enrolled into the study.

• Confirmed diagnosis by any method of an infection as a major cause of illnesses leading to hospitalization. For example, a patient who already has had a definite diagnosis of malarial infection by blood smear.
• Clinical diagnosis of any specific disease or any specific syndromes such as acute infective diarrhea, acute pneumonia, acute encephalomyelitis and acute myocarditis.
• Suspected of having both infectious and non-infectious diseases and infectious disease is a primary cause of illnesses (primary diagnosis) leading to the hospitalization. For example, acute pneumonia with stroke as an underlying disease, etc.
• Patients who are admitted to other hospitals and referred to the study site. For example a referred patient who admit to the first hospital less than 24 hours prior to enrollment.

Related Conditions & MeSH terms

• Community-Acquired Infections
• Sepsis
• Toxemia

Intervention

Other:
• Specimens collection
On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site. Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.

Locations

Country	Name	City	State
Thailand	Sappasithiprasong Hospital	Ubon Ratchathani

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	Mahidol Oxford Tropical Medicine Research Unit, Sanpasitthiprasong Hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	28-day mortality after admission date		2.5 years
Secondary	Causative organisms of community-acquired sepsis		2.5 years
Secondary	Respiration: Blood gas (PaO2 [mmHg])	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Respiration: Type of oxygen support	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Respiration: FiO2 (% )	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Respiration: SpO2 by pulse oximeter level (%)	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Coagulation: Platelet (per µL)	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Liver: Total Bilirubin (mg/dL)	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Cardiovascular: Mean Arterial Pressure (MAP) at enrolment (mmHg)	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Cardiovascular: Dosages (µg/kg/min) of inotropic	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Cardiovascular: Dosages (µg/kg/min) of vasopressor agents	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Central nervous system: Glasgow Coma Score	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Renal: Creatinine (mg/sdL)	Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)	2.5 years
Secondary	Hematology	Other laboratory measurement	2.5 years
Secondary	Blood chemistry	Other laboratory measurement	2.5 years
Secondary	Causes of sepsis associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand		2.5 years
Secondary	Sepsis resuscitation associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand		2.5 years
Secondary	Antimicrobial treatment associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand		2.5 years
Secondary	Inflammatory associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand		2.5 years
Secondary	Genetics factors with mortality outcome in patients with community-acquired sepsis in northeast Thailand		2.5 years
Secondary	Diagnostic tests for infection in community-acquired sepsis in NE Thailand		2.5 years